Disclosed are pyridazine-containing compounds and pharmaceutical compositions of Formula (I), salts thereof, and methods for their preparation. Specific examples of compounds of Formula (I) include 2-[(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2]bipyrazinyl-5-yl]-propan-2-ol, 2-{ (R)-4-[6-(Hyrdoxyl-phenyl-methyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2]bipyrazinyl-5-yl]-propan-2-ol, and 1-[(R)-4-(6-Benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2]bipyrazinyl-5-yl]-ethanone. Also disclosed is a method of treating a disease, disorder or syndrome associated with Smoothened inhibition, such as cancer or inflammation, which comprises the administration of a compound or pharmaceutical of Formula (I). Treatable cancers include medulloblastoma, basal cell carcinoma, pancreatic cancer, and small cell lung cancer.
